Cargando…

Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States

Hepatitis C virus (HCV) infection is the main cause of hepatocellular carcinoma (HCC) in the United States (US) and an increasingly common cause of HCC in China. We aimed to evaluate the incidence and risk factors of HCC in HCV patients in the US and China. 795 HCV RNA + patients without HCC from Un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Ming, Parikh, Neehar D., Liu, Huixin, Wu, Elizabeth, Rao, Huiying, Feng, Bo, Lin, Andy, Wei, Lai, Lok, Anna S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708980/ https://www.ncbi.nlm.nih.gov/pubmed/33262356 http://dx.doi.org/10.1038/s41598-020-77515-y

Ejemplares similares

Comparison of clinical outcomes and impact of SVR in American and Chinese patients with chronic hepatitis C
por: Rao, Huiying, et al.
Publicado: (2020)

Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis
por: Tapper, Elliot B., et al.
Publicado: (2019)

The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma
por: Parikh, Neehar D., et al.
Publicado: (2016)

Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study
por: Tapper, Elliot B, et al.
Publicado: (2018)

Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic
por: Mehta, Neil, et al.
Publicado: (2021)

Patient Education Improves Patient Knowledge and Acceptance on Antiviral Therapy of Hepatitis C in Rural China
por: Yang, Ming, et al.
Publicado: (2017)

Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States
por: Liu, Pian, et al.
Publicado: (2017)

Ambient ultraviolet radiation exposure and hepatocellular carcinoma incidence in the United States
por: VoPham, Trang, et al.
Publicado: (2017)

Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas in the United States: Similarities and Differences
por: Ng, Jennifer, et al.
Publicado: (2012)

Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update
por: Lok, James, et al.
Publicado: (2021)

Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy
por: Bonafede, Machaon M., et al.
Publicado: (2019)

Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis
por: Marquardt, Patrick, et al.
Publicado: (2021)

Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
por: Parikh, Neehar D., et al.
Publicado: (2018)

Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort
por: Parikh, Neehar D., et al.
Publicado: (2022)

A Fucosylated Glycopeptide as a Candidate Biomarker for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation
por: Lin, Yu, et al.
Publicado: (2022)

Viral Hepatitis and Hepatocellular Carcinoma: State of the Art
por: Datfar, Toofan, et al.
Publicado: (2021)

Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies
por: Liang, Jing, et al.
Publicado: (2019)

A Biomarker Panel Based upon AFP, Fucosylated Kininogen and PEG-Precipitated IgG Is Highly Accurate for the Early Detection Hepatocellular Carcinoma in Patients with Cirrhosis in Phase II and Phase III Biomarker Evaluation
por: Wang, Mengjun, et al.
Publicado: (2022)

Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma
por: Singal, Amit G, et al.
Publicado: (2016)

Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study
por: Parikh, Neehar D., et al.
Publicado: (2023)

Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States
por: Zheng, Rongshou, et al.
Publicado: (2023)

Comparison of a multitarget blood test to ultrasound and alpha‐fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta‐analysis
por: Singal, Amit G., et al.
Publicado: (2022)

Stage migration as a surrogate of survival in hepatocellular carcinoma treated with transarterial chemoembolization
por: Kassab, Ihab, et al.
Publicado: (2023)

TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis
por: Brown, Andrew M., et al.
Publicado: (2022)

Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States
por: Nguyen, Mindie H., et al.
Publicado: (2022)

The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area
por: Taura, Naota, et al.
Publicado: (2011)

Telomere Length and Survival of Patients with Hepatocellular Carcinoma in the United States
por: Yang, Baiyu, et al.
Publicado: (2016)

Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan
por: Lin, Yih-Jyh, et al.
Publicado: (2020)

Stereotactic Ablative Radiotherapy Fractionation for Hepatocellular Carcinoma in the United States
por: Sheth, Niki, et al.
Publicado: (2020)

FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China
por: Chen, YanHui, et al.
Publicado: (2013)

Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma
por: Parikh, Neehar D., et al.
Publicado: (2022)

Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis
por: Zhang, Wei, et al.
Publicado: (2019)

Comprehensive Health‐State Utilities in Contemporary Patients With Cirrhosis
por: Foster, Chelsey, et al.
Publicado: (2020)

Decoding the Roles of Long Noncoding RNAs in Hepatocellular Carcinoma
por: Wong, Lok-Sze, et al.
Publicado: (2021)

The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019
por: Yang, Jia, et al.
Publicado: (2023)

Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C
por: Perumalswami, Ponni V., et al.
Publicado: (2022)

Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2021)

Liver Transplantation for Hepatocellular Carcinoma among African Americans in the United States
por: Sourianarayanane, A., et al.
Publicado: (2012)

PRM-MS Quantitative Analysis of Isomeric N-Glycopeptides Derived from Human Serum Haptoglobin of Patients with Cirrhosis and Hepatocellular Carcinoma
por: Gutierrez Reyes, Cristian D., et al.
Publicado: (2021)

The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma
por: Lai, Quirino, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7oo872v812qoub4rji4fdm1q4g